Skip to main content

Press Releases View all 56 hits

Sobi™ signs manufacturing agreements with Pfizer

Sobi™ signs manufacturing agreements with Pfizer

Press Releases   •   Apr 29, 2016 06:05 GMT

Sobi has extended the existing manufacturing agreement with Pfizer for the drug substance for ReFacto AF®/XYNTHA® until December 31, 2023. In addition, Sobi has decided to move production of Kineret® drug substance to Pfizer’s manufacturing site in Strängnäs, Sweden.

Sobi™ publishes its report for the first quarter 2016

Sobi™ publishes its report for the first quarter 2016

Press Releases   •   Apr 27, 2016 06:00 GMT

Sobi™ today announced its results for the first quarter 2016. Revenue for the quarter totalled SEK 1,273 M (865), an increase of 47 per cent compared to previous year. All parts of the business contributed to the result with Orfadin® and Kineret® delivering strong performance.

Sobi publishes 2015 Annual Report

Sobi publishes 2015 Annual Report

Press Releases   •   Apr 27, 2016 05:45 GMT

Sobi today published its 2015 Annual Report, themed “A new chapter of our story”. The integrated report summarises the business as well as financial highlights for 2015, and gives a deeper insight into the company’s strategic agenda and its patient-centric innovation model.

Bo Jesper Hansen to step down as Chairman of Sobi™ – Håkan Björklund to be nominated as new Chairman of the Board

Bo Jesper Hansen to step down as Chairman of Sobi™ – Håkan Björklund to be nominated as new Chairman of the Board

Press Releases   •   Feb 26, 2016 07:15 GMT

Sobi Chairman of the Board, Bo Jesper Hansen, MD, PhD, has informed the Sobi’s nomination committee that he will not stand for re-election at the 2016 annual general meeting of shareholders (AGM). The Nomination Committee will propose that the shareholders elect Håkan Björklund, PhD, as the new Chairman of the Board for Sobi.

Images 4 hits

Bo Jesper Hansen

Bo Jesper Hansen

Chairman of the Board, Sobi

License Creative Commons Attribution
Download
Size

70.7 KB • 1000 x 667 px

Annette Clancy joins Sobi’s Board of Directors

Annette Clancy joins Sobi...

Annette Clancy has over 30 years of experience in the Pharmaceutical and Biotechnology Industry, working in a variety of roles in the US ...

License Creative Commons Attribution
Download
Size

13.5 MB • 3744 x 5616 px

Sobi logo

Sobi logo

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therap...

License Creative Commons Attribution
Download
Size

155 KB • 1307 x 615 px

Charlotte af Klercker, Senior Communications Manager

Charlotte af Klercker, Se...

License Creative Commons Attribution
Download
Size

10.1 MB • 5760 x 3840 px

Videos 3 hits

Haemophilia therapy from largest multi-year donation now available to patients in developing world

Haemophilia therapy from ...

Biogen, Sobi and the World Federation of Hemophilia collaboration to enable a sustained humanitarian supply of haemophilia treatment with...

License Creative Commons Attribution
Download
Size

854 x 480 px

Biogen Idec and Sobi to donate 1 billion international units of clotting factor to support treatment of haemophilia in developing world

Biogen Idec and Sobi to d...

Biogen Idec and Sobi intend to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in ...

License Creative Commons Attribution
Download
Size

90.6 MB • 854 x 480 px

CEO Geoff McDonough discusses Q1 2014

CEO Geoff McDonough discu...

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the first quarter 2014. Revenues totalled SEK 573.3 M (528.5), ...

License Creative Commons Attribution
Download
Size

194 MB • 854 x 480 px

Documents 2 hits

Sobi™ publishes 2015 Annual Report

Sobi™ publishes 2015 Annual Report

Documents   •   Apr 27, 2016 05:45 GMT

Sobi's Annual Report 2015 is themed “A new chapter of our story”. The integrated report summarises the business as well as financial highlights for 2015, and gives a deeper insight into the company’s strategic agenda and its patient-centric innovation model. The 2015 Annual Report is available both in print and as an interactive online version.

Sobi Q1 Report 2014

Sobi Q1 Report 2014

Documents   •   May 08, 2014 09:04 GMT

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the first quarter 2014. Revenues totalled SEK 573.3 M (528.5), an increase of 8 per cent. The Partner Products portfolio was a highlight, with 70 per cent growth compared to the first quarter last year.

Contacts 1 hit

  • Press Contact
  • Senior Communications Manager
  • Charlotte.afklercker@sobi.com
  • 0707-297327